EA029504B1 - Способ индуцирования иммунного ответа против филовирусного антигена у пациента с использованием аденовирусов серотипа 26 и серотипа 35 - Google Patents
Способ индуцирования иммунного ответа против филовирусного антигена у пациента с использованием аденовирусов серотипа 26 и серотипа 35 Download PDFInfo
- Publication number
- EA029504B1 EA029504B1 EA201390866A EA201390866A EA029504B1 EA 029504 B1 EA029504 B1 EA 029504B1 EA 201390866 A EA201390866 A EA 201390866A EA 201390866 A EA201390866 A EA 201390866A EA 029504 B1 EA029504 B1 EA 029504B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- vectors
- individuals
- virus
- vaccination
- antigen
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 63
- 102000036639 antigens Human genes 0.000 title claims abstract description 62
- 108091007433 antigens Proteins 0.000 title claims abstract description 62
- 230000028993 immune response Effects 0.000 title claims abstract description 54
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 47
- 241000711950 Filoviridae Species 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 25
- 230000001939 inductive effect Effects 0.000 title claims abstract description 11
- 239000013598 vector Substances 0.000 claims abstract description 167
- 229960005486 vaccine Drugs 0.000 claims description 75
- 238000002255 vaccination Methods 0.000 claims description 62
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 150000007523 nucleic acids Chemical class 0.000 claims description 33
- 108020004707 nucleic acids Proteins 0.000 claims description 30
- 102000039446 nucleic acids Human genes 0.000 claims description 30
- 108090000565 Capsid Proteins Proteins 0.000 claims description 23
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108090000288 Glycoproteins Proteins 0.000 claims description 13
- 102000003886 Glycoproteins Human genes 0.000 claims description 11
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 210000000234 capsid Anatomy 0.000 claims description 2
- 241000700605 Viruses Species 0.000 description 53
- 210000004027 cell Anatomy 0.000 description 51
- 241000282553 Macaca Species 0.000 description 45
- 230000036039 immunity Effects 0.000 description 42
- 208000015181 infectious disease Diseases 0.000 description 42
- 239000002245 particle Substances 0.000 description 41
- 239000013256 coordination polymer Substances 0.000 description 36
- 241001465754 Metazoa Species 0.000 description 33
- 230000004044 response Effects 0.000 description 32
- 239000000203 mixture Substances 0.000 description 30
- 230000001681 protective effect Effects 0.000 description 28
- 241000282414 Homo sapiens Species 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 21
- 230000003612 virological effect Effects 0.000 description 19
- 108090000765 processed proteins & peptides Chemical group 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 16
- 230000003053 immunization Effects 0.000 description 15
- 238000002649 immunization Methods 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 208000022531 anorexia Diseases 0.000 description 14
- 206010061428 decreased appetite Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 241001115402 Ebolavirus Species 0.000 description 13
- 230000018044 dehydration Effects 0.000 description 13
- 238000006297 dehydration reaction Methods 0.000 description 13
- 230000002163 immunogen Effects 0.000 description 13
- 208000010201 Exanthema Diseases 0.000 description 12
- 201000005884 exanthem Diseases 0.000 description 12
- 206010037844 rash Diseases 0.000 description 12
- 241000282693 Cercopithecidae Species 0.000 description 11
- 229920001184 polypeptide Chemical group 0.000 description 11
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 10
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 230000008348 humoral response Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000024932 T cell mediated immunity Effects 0.000 description 6
- 230000005867 T cell response Effects 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 101710121417 Envelope glycoprotein Proteins 0.000 description 4
- 208000007136 Filoviridae Infections Diseases 0.000 description 4
- 102100021696 Syncytin-1 Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 101100228922 Caenorhabditis elegans glb-26 gene Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241001115401 Marburgvirus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241000598171 Human adenovirus sp. Species 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000008349 antigen-specific humoral response Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940031689 heterologous vaccine Drugs 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 1
- 235000005749 Anthriscus sylvestris Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 101000604876 Homo sapiens Kremen protein 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102100038173 Kremen protein 1 Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710149210 Putative non-structural protein Proteins 0.000 description 1
- 206010037868 Rash maculo-papular Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- -1 carrier Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000000852 deltoid muscle Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 108700010787 filovirus proteins Proteins 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000012965 maculopapular rash Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- PKAHQJNJPDVTDP-UHFFFAOYSA-N methyl cyclopropanecarboxylate Chemical compound COC(=O)C1CC1 PKAHQJNJPDVTDP-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940023867 prime-boost vaccine Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42295410P | 2010-12-14 | 2010-12-14 | |
| PCT/US2011/064944 WO2012082918A1 (en) | 2010-12-14 | 2011-12-14 | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201390866A1 EA201390866A1 (ru) | 2014-05-30 |
| EA029504B1 true EA029504B1 (ru) | 2018-04-30 |
Family
ID=46245095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201390866A EA029504B1 (ru) | 2010-12-14 | 2011-12-14 | Способ индуцирования иммунного ответа против филовирусного антигена у пациента с использованием аденовирусов серотипа 26 и серотипа 35 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9701718B2 (enExample) |
| EP (1) | EP2655604B1 (enExample) |
| JP (2) | JP6054876B2 (enExample) |
| KR (1) | KR101879892B1 (enExample) |
| CN (1) | CN103370411B (enExample) |
| AU (1) | AU2011343798B2 (enExample) |
| BR (1) | BR112013014712B1 (enExample) |
| CA (1) | CA2821289C (enExample) |
| DK (1) | DK2655604T3 (enExample) |
| EA (1) | EA029504B1 (enExample) |
| ES (1) | ES2676196T3 (enExample) |
| PL (1) | PL2655604T3 (enExample) |
| WO (1) | WO2012082918A1 (enExample) |
| ZA (1) | ZA201304260B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101879892B1 (ko) | 2010-12-14 | 2018-08-17 | 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 | 아데노바이러스 혈청형 26 및 혈청형 35 필로바일러스 백신 |
| ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| CA2952741A1 (en) | 2014-06-26 | 2015-12-30 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| AU2015311852B2 (en) | 2014-09-03 | 2018-12-13 | Bavarian Nordic A/S | Methods and compositions for inducing protective immunity against filovirus infection |
| KR20190062617A (ko) | 2014-09-03 | 2019-06-05 | 버베리안 노딕 에이/에스 | 면역 반응을 증대시키기 위한 방법 및 조성물 |
| MA40765B1 (fr) | 2014-09-26 | 2021-04-30 | Beth Israel Deaconess Medical Ct Inc | Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine |
| EP3271729B1 (en) | 2015-03-18 | 2020-09-23 | Janssen Vaccines & Prevention B.V. | Assays for recombinant expression systems |
| PL3390430T3 (pl) | 2015-12-15 | 2020-03-31 | Janssen Vaccines & Prevention B.V. | Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania |
| CN108697591B (zh) | 2016-02-18 | 2022-06-17 | 国际香料和香精公司 | 聚脲胶囊组合物 |
| EP3429740B1 (en) | 2016-03-18 | 2021-05-05 | International Flavors & Fragrances Inc. | Silica microcapsules and methods of preparing same |
| EA201892735A1 (ru) | 2016-06-16 | 2019-05-31 | Янссен Вэксинс Энд Превеншн Б.В. | Состав вакцины против hiv |
| CN109414376A (zh) | 2016-07-01 | 2019-03-01 | 国际香料和香精公司 | 稳定的微胶囊组合物 |
| US10925956B2 (en) | 2016-07-15 | 2021-02-23 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| EP3484505A1 (en) | 2016-07-15 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| EP4209264A1 (en) | 2016-09-16 | 2023-07-12 | International Flavors & Fragrances Inc. | Microcapsule compositions stabilized with viscosity control agents |
| US20180085291A1 (en) | 2016-09-28 | 2018-03-29 | International Flavors & Fragrances Inc. | Microcapsule compositions containing amino silicone |
| WO2018185732A1 (en) | 2017-04-06 | 2018-10-11 | Janssen Vaccines & Prevention B.V. | Mva-bn and ad26.zebov or ad26.filo prime-boost regimen |
| US20180346648A1 (en) | 2017-05-30 | 2018-12-06 | International Flavors & Fragrances Inc. | Branched polyethyleneimine microcapsules |
| BR112019026126A2 (pt) | 2017-06-15 | 2020-06-30 | Janssen Vaccines & Prevention B.V. | vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos |
| US20190022212A1 (en) | 2017-07-21 | 2019-01-24 | Beth Israel Deaconess Medical Center, Inc. | Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human |
| WO2019023566A1 (en) * | 2017-07-28 | 2019-01-31 | Janssen Vaccines & Prevention B.V. | METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP |
| WO2019099970A1 (en) | 2017-11-20 | 2019-05-23 | Janssen Pharmaceuticals Inc. | Method of providing safe administration of adenoviral vectors encoding a zika virus antigen |
| JP2021506300A (ja) | 2017-12-19 | 2021-02-22 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Ｂ型肝炎ウイルス（ｈｂｖ）に対する免疫応答を誘導するための方法および組成物 |
| CN112041361B (zh) | 2018-04-27 | 2023-06-30 | 国际香料和香精公司 | 稳定的聚脲微胶囊组合物 |
| EP3810277A1 (en) | 2018-07-20 | 2021-04-28 | Janssen Vaccines & Prevention B.V. | Recombinant adenoviral vector expressing zika antigen with improved productivity |
| WO2020064621A1 (en) | 2018-09-25 | 2020-04-02 | Janssen Vaccines & Prevention B.V. | Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components |
| BR112021011942A2 (pt) | 2018-12-18 | 2021-09-08 | International Flavors & Fragrances Inc. | Microcápsula, processo para preparar uma composição de microcápsula, composição de microcápsula, e, produto de consumo |
| WO2020131879A2 (en) | 2018-12-18 | 2020-06-25 | International Flavors & Fragrances Inc. | Protein microcapsules and method of preparing the same |
| WO2020229906A1 (en) | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Efficient impurity removal using a diafiltration process |
| TW202204380A (zh) | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗 |
| KR20230009445A (ko) | 2020-05-11 | 2023-01-17 | 얀센 파마슈티칼즈, 인코포레이티드 | 안정화된 코로나바이러스 스파이크 단백질 융합 단백질 |
| EP4171627A1 (en) | 2020-06-29 | 2023-05-03 | Janssen Vaccines & Prevention B.V. | Vaccine combination against respiratory syncytial virus infection |
| BR112022026974A2 (pt) | 2020-07-06 | 2023-01-24 | Janssen Pharmaceuticals Inc | Proteínas de fusão estabilizadas de proteínas de pico de coronavírus |
| IL299571A (en) | 2020-07-08 | 2023-02-01 | Janssen Sciences Ireland Unlimited Co | Rna replicon vaccines against hbv |
| RU2731356C9 (ru) * | 2020-08-22 | 2021-10-05 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты) |
| US20240228548A9 (en) | 2021-02-19 | 2024-07-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
| AU2022249741A1 (en) | 2021-04-01 | 2023-09-21 | Msd International Business Gmbh | Stabilized pre-fusion piv3 f proteins |
| EP4124383A1 (en) | 2021-07-27 | 2023-02-01 | International Flavors & Fragrances Inc. | Biodegradable microcapsules |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023026182A1 (en) | 2021-08-24 | 2023-03-02 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| EP4154974A1 (en) | 2021-09-23 | 2023-03-29 | International Flavors & Fragrances Inc. | Biodegradable microcapsules |
| WO2023047348A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
| WO2023047349A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| EP4448802A1 (en) | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
| US20260085096A1 (en) | 2022-09-23 | 2026-03-26 | Janssen Vaccines & Prevention B.V. | Stabilized trimeric class i fusion proteins |
| EP4590690A1 (en) | 2022-09-23 | 2025-07-30 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
| WO2024061759A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
| WO2024074584A1 (en) | 2022-10-06 | 2024-04-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion piv3 f proteins |
| EP4406641A1 (en) | 2023-01-26 | 2024-07-31 | International Flavors & Fragrances Inc. | Biodegradable microcapsules containing low log p fragrance |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006037038A1 (en) * | 2004-09-27 | 2006-04-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Optimized vaccines to provide protection against ebola and other viruses |
| WO2006040330A2 (en) * | 2004-10-13 | 2006-04-20 | Crucell Holland B.V. | Improved adenoviral vectors and uses thereof |
| US20100303857A1 (en) * | 2001-10-01 | 2010-12-02 | Health and Human Services, the Government of the U.S.A. as Represented by the Secretary, Department | Development of a preventive vaccine for filovirus infection in primates |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6852324B1 (en) * | 1997-12-23 | 2005-02-08 | The United States Of America As Represented By The Department Of Health And Human Services | Immunization for ebola virus infection |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| WO2003104467A1 (en) | 2002-04-25 | 2003-12-18 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
| CA2478508C (en) | 2002-04-25 | 2013-07-02 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| EP1553983A2 (en) * | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| AU2004262022B2 (en) * | 2003-08-01 | 2010-10-28 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Accelerated vaccination |
| CN101072879B (zh) * | 2004-10-13 | 2011-05-11 | 克鲁塞尔荷兰公司 | 改良的腺病毒载体及其应用 |
| BRPI0518146A (pt) * | 2004-10-14 | 2008-10-28 | Crucell Holland Bv | kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária |
| WO2007104792A2 (en) * | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| WO2007110409A1 (en) * | 2006-03-27 | 2007-10-04 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
| WO2009092113A2 (en) * | 2008-01-19 | 2009-07-23 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the delivery of vaccines to disrupted epithelium |
| KR101879892B1 (ko) | 2010-12-14 | 2018-08-17 | 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 | 아데노바이러스 혈청형 26 및 혈청형 35 필로바일러스 백신 |
-
2011
- 2011-12-14 KR KR1020137016833A patent/KR101879892B1/ko not_active Expired - Fee Related
- 2011-12-14 JP JP2013544747A patent/JP6054876B2/ja active Active
- 2011-12-14 EP EP11849865.8A patent/EP2655604B1/en active Active
- 2011-12-14 CA CA2821289A patent/CA2821289C/en active Active
- 2011-12-14 WO PCT/US2011/064944 patent/WO2012082918A1/en not_active Ceased
- 2011-12-14 PL PL11849865T patent/PL2655604T3/pl unknown
- 2011-12-14 EA EA201390866A patent/EA029504B1/ru not_active IP Right Cessation
- 2011-12-14 BR BR112013014712-1A patent/BR112013014712B1/pt not_active IP Right Cessation
- 2011-12-14 ES ES11849865.8T patent/ES2676196T3/es active Active
- 2011-12-14 CN CN201180067429.7A patent/CN103370411B/zh active Active
- 2011-12-14 US US13/994,532 patent/US9701718B2/en active Active
- 2011-12-14 DK DK11849865.8T patent/DK2655604T3/en active
- 2011-12-14 AU AU2011343798A patent/AU2011343798B2/en not_active Ceased
-
2013
- 2013-06-10 ZA ZA2013/04260A patent/ZA201304260B/en unknown
-
2016
- 2016-10-21 JP JP2016206679A patent/JP6268258B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100303857A1 (en) * | 2001-10-01 | 2010-12-02 | Health and Human Services, the Government of the U.S.A. as Represented by the Secretary, Department | Development of a preventive vaccine for filovirus infection in primates |
| WO2006037038A1 (en) * | 2004-09-27 | 2006-04-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Optimized vaccines to provide protection against ebola and other viruses |
| WO2006040330A2 (en) * | 2004-10-13 | 2006-04-20 | Crucell Holland B.V. | Improved adenoviral vectors and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| Geisbert T. W. et al. "Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge", Journal of Virology, 2011, 85 (9), 4222-4233. The whole document * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20140017278A1 (en) | 2014-01-16 |
| JP2014503206A (ja) | 2014-02-13 |
| EA201390866A1 (ru) | 2014-05-30 |
| BR112013014712B1 (pt) | 2021-03-02 |
| JP2017048207A (ja) | 2017-03-09 |
| BR112013014712A2 (pt) | 2017-06-06 |
| DK2655604T3 (en) | 2018-08-06 |
| WO2012082918A1 (en) | 2012-06-21 |
| AU2011343798B2 (en) | 2016-07-14 |
| PL2655604T3 (pl) | 2019-02-28 |
| KR20140019304A (ko) | 2014-02-14 |
| EP2655604A4 (en) | 2015-01-28 |
| US9701718B2 (en) | 2017-07-11 |
| ES2676196T3 (es) | 2018-07-17 |
| AU2011343798A1 (en) | 2013-07-11 |
| KR101879892B1 (ko) | 2018-08-17 |
| ZA201304260B (en) | 2021-05-26 |
| CN103370411A (zh) | 2013-10-23 |
| CN103370411B (zh) | 2016-05-04 |
| EP2655604B1 (en) | 2018-05-09 |
| CA2821289C (en) | 2019-05-21 |
| JP6268258B2 (ja) | 2018-01-24 |
| JP6054876B2 (ja) | 2016-12-27 |
| CA2821289A1 (en) | 2012-06-21 |
| EP2655604A1 (en) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101879892B1 (ko) | 아데노바이러스 혈청형 26 및 혈청형 35 필로바일러스 백신 | |
| US11918639B2 (en) | Methods and compositions for inducing protective immunity against filovirus infection | |
| JP2019123734A (ja) | 免疫応答の増進を目的とする方法及び組成物 | |
| Auperin | Construction and evaluation of recombinant virus vaccines for Lassa fever | |
| US20220372515A1 (en) | Adenovirus vectors and uses thereof | |
| HK1239544B (en) | Methods and compositions for inducing protective immunity against filovirus infection | |
| HK1239544A1 (en) | Methods and compositions for inducing protective immunity against filovirus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |